Maternal separation increases alcohol-drinking behaviour and reduces endocannabinoid levels in the mouse striatum and prefrontal cortex

Portero-Tresserra, Marta ; Gracia-Rubio, Irene ; Cantacorps, Lídia ; Pozo, Oscar J. ; Gómez-Gómez, Alejandro ; Pastor, Antoni ; López-Arnau, Raúl ; de la Torre, Rafael ; Valverde, Olga

Resumen: Childhood adversity is associated with an increased risk of mood, anxiety and substance use disorders. Maternal separation is a reliable rodent model of early life adversity that leads to depression-like symptoms, which may increase the vulnerability to alcohol consumption during adolescence. However, the specific alterations in the pattern of alcohol consumption induced by maternal separation and the underlying molecular mechanisms are still unclear. The purpose of this study is to evaluate the long-term effects of maternal separation with early weaning (MSEW) on emotional and social behaviour, alcohol rewarding properties, and alcohol consumption, abstinence and relapse in adolescent male C57BL/6 mice. In addition, endocannabinoid and monoamine levels were analysed in discrete brain areas. Results showed that MSEW mice presented emotional alterations related to depressive-like behaviour and modified endocannabinoid levels in the striatum and the prefrontal cortex. MSEW mice also showed impairments in alcohol-induced conditioned place preference and higher alcohol intake in a model of binge drinking. Moreover, MSEW animals displayed a higher propensity to relapse in the two-bottle choice paradigm following a period of alcohol abstinence associated with reduced monoamine levels in the striatum. Such results indicate that exposure to early life stress increased the vulnerability to alcohol binge-drinking during adolescence, which may be partially explained by decreased sensitivity to alcohol rewarding properties and the ability to potentiate alcohol intake following a period of abstinence.

Idioma: Inglés

DOI: 10.1016/j.euroneuro.2018.02.003

Año: 2018

Publicado en: EUROPEAN NEUROPSYCHOPHARMACOLOGY 28, 4 (2018), [41 pp.]
ISSN: 0924-977X

Factor impacto JCR: 4.468 (2018)

Categ. JCR: CLINICAL NEUROLOGY rank: 33 / 199 = 0.166 (2018) - Q1 - T1
Categ. JCR: PSYCHIATRY rank: 27 / 146 = 0.185 (2018) - Q1 - T1
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 35 / 266 = 0.132 (2018) - Q1 - T1
Categ. JCR: NEUROSCIENCES rank: 63 / 266 = 0.237 (2018) - Q1 - T1

Factor impacto SCIMAGO: 1.911 - Biological Psychiatry (Q1) - Neurology (Q1) - Psychiatry and Mental Health (Q1) - Pharmacology (Q1) - Pharmacology (medical) (Q1) - Neurology (clinical) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CPII16-00027
Financiación: info:eu-repo/grantAgreement/ES/MINECO SAF2016-75966-R
Financiación: info:eu-repo/grantAgreement/ES/MSCBS/Plan Nacional sobre Drogas 02-2014

Tipo y forma: Article (PostPrint)